MODULATION OF THE IN-VITRO CARDIOTOXICITY OF DOXORUBICIN BY FLAVONOIDS

被引:39
|
作者
HUSKEN, BCP
DEJONG, J
BEEKMAN, B
ONDERWATER, RCA
VANDERVIJGH, WJF
BAST, A
机构
[1] FREE UNIV AMSTERDAM,FAC CHEM,DIV MOLEC PHARMACOL,LEIDEN AMSTERDAM CTR DRUG RES,1081 HV AMSTERDAM,NETHERLANDS
[2] FREE UNIV AMSTERDAM HOSP,DEPT ONCOL,1081 HV AMSTERDAM,NETHERLANDS
关键词
FLAVONOIDS; DOXORUBICIN IRON COMPLEX; ICRF-187;
D O I
10.1007/s002800050367
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer therapy with the anthracycline doxorubicin (Dox) is limited by cardiomyopathy, which develops in animals and patients after cumulative dosing. Generation of free radicals by Dox may be involved in this cardiotoxicity. Dox binds strongly to metal ions, especially iron(III). This Dox-metal complex stimulates the generation of free radicals through self-reduction of the complex. We investigated the possibility of inhibiting Dox-induced cardiotoxicity by scavenging of free radicals and/or chelating metal ions. The effects of Dox, both alone and in combination with iron-chelating agents, were studied on inotropy of the isolated mouse left atrium, lipid peroxidation (LPO) in cardiac microsomal membranes, ferricytochrome c (Cyt.C3+) reduction, and oxygen consumption. The flavonoids 7-monohydroxyethylrutoside (mono-HER) and 7,3',4'-trihydroxyethylrutoside (tri-HER) and the ethylenediaminetetraacetic acid (EDTA) analogue ICRF-198 and its precursor ICRF-187 were used as iron-chelating agents. The latter were used for comparison since 1CRF-187 has been reported to inhibit the cardiotoxic effects of Dox both in vitro and in vivo. Only the flavonoids could inhibit the negative inotropic effect of Dox (35 mu M) on the mouse left atrium; in the presence of tri-HER (500 mu M) the beating force decreased by 18% instead of 50%, whereas mono-HER completely prevented the Dox-induced negative inotropic effect. ICRF-19X and both flavonoids (500 mu M) completely inhibited Dox (35 mu M)-induced LPO, whereas ICRF-187 provided 65% inhibition. The observation that both cyt.c(3+) reduction and oxygen consumption induced by the Dox-iron(III) complex (50/16.6 mu M Dox(3)Fe(3+)) could be inhibited by superoxide dismutase proved the involvement of superoxide anions (O-2(.-)). The iron-chelating agents (50 mu M) inhibited Cyt.C3+ reduction by 91% (mono-HER), 43% (tri-HER), and 100% (1CRF-198). Only mono-HER and ICRF-198 (50 mu M) were capable of inhibiting the oxygen consumption by 70% and 43%, respectively. It is concluded that flavonoids offer a good perspective for further studies on the prevention of Dox-induced cardiomyopathy.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 50 条
  • [1] Protectors against doxorubicin-induced cardiotoxicity: Flavonoids
    A. Bast
    H. Kaiserová
    G. J. M. den Hartog
    G. R. M. M. Haenen
    W. J. F. van der Vijgh1
    Cell Biology and Toxicology, 2007, 23 : 39 - 47
  • [3] Protectors against doxorubicin-induced cardiotoxicity:: Flavonoids
    Bast, A.
    Kaiserova, H.
    den Hartog, G. J. M.
    Haenen, G. R. M. M.
    van der Vijgh, W. J. F.
    CELL BIOLOGY AND TOXICOLOGY, 2007, 23 (01) : 39 - 47
  • [4] Protective effect of flavonoids on doxorubicin-induced cardiotoxicity
    Sadzuka, Y
    Sugiyama, T
    Shimoi, K
    Kinae, N
    Hirota, S
    TOXICOLOGY LETTERS, 1997, 92 (01) : 1 - 7
  • [5] Propolis flavonoids liposome ameliorate doxorubicin-induced cardiotoxicity in rats
    Ghazi, Ali M.
    Latif, Sijad M.
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2023, 30 (04): : E230 - E240
  • [6] Flavonoids reduce morphine withdrawal in-vitro
    Capasso, A
    Piacente, S
    Pizza, C
    Sorrentino, L
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (05) : 561 - 564
  • [7] The Role of Flavonoids as a Cardioprotective Strategy against Doxorubicin-Induced Cardiotoxicity: A Review
    Syahputra, Rony Abdi
    Harahap, Urip
    Dalimunthe, Aminah
    Nasution, M. Pandapotan
    Satria, Denny
    MOLECULES, 2022, 27 (04):
  • [8] New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity
    Van Acker, FAA
    Hulshof, JW
    Haenen, GRMM
    Menge, WMPB
    van der Vijgh, WJF
    Bast, A
    FREE RADICAL BIOLOGY AND MEDICINE, 2001, 31 (01) : 31 - 37
  • [9] DOXORUBICIN CARDIOTOXICITY
    UNVERFERTH, DV
    MAGORIEN, RD
    LEIER, CV
    BALCERZAK, SP
    CANCER TREATMENT REVIEWS, 1982, 9 (02) : 149 - 164
  • [10] DOXORUBICIN CARDIOTOXICITY
    CARTER, JM
    BERGIN, PS
    NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (17): : 1118 - 1119